Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05675449 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT05675449 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Pfizer. The registered enrollment target is 90 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT05675449, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optimal dose(s) of elranatamab plus maplirpacept. All study medicines are given over 4-week cycles. Everyone taking part in this study will receive elranatamab as a shot under the skin. Participants in Part 1 will also receive weekly carfilzomib as an IV infusion (given directly into a vein) and dexamethasone either by mouth (as a pill) or by IV infusion. Participants in Part 2 will receive elranatamab in combination with maplirpacept as an IV infusion (given directly into a vein) The investigators will examine the experiences of people receiving the study medicines. This will help determine if the study medicines are safe and can be used for multiple myeloma treatment. Participants will take part in this study for about 2 years after the first dose.
Conditions Studied
Interventions
- DRUG Elranatamab
- DRUG Carfilzomib
- DRUG Maplirpacept
Study Locations (20)
Florida
- Sylvester Comprehensive Cancer Center - Aventura - Aventura
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center - Coral Gables
- Sylvester Comprehensive Cancer Center - Coral Springs - Coral Springs
- University of Miami Hospital and Clinics - Deerfield Beach - Deerfield Beach
- Sylvester Comprehensive Cancer Center - Hollywood - Hollywood
- Griffin Cancer Research Building (GCRB) - Miami
- Sylvester Comprehensive Cancer Center - Miami
- University of Miami Hospital and Clinics - Miami
- Sylvester Comprehensive Cancer Center - Kendall - Miami
- Sylvester Comprehensive Cancer Center - Plantation - Plantation
California
- Beverly Hills Cancer Center - Beverly Hills
- Clinical Research Advisors (Encino Satellite Location) - Encino
- Clinical Research Advisors (Korea Town Satellite Location) - Los Angeles
- Clinical Research Advisors (West Hollywood Satellite Location) - Los Angeles
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University Administration Office - Atlanta
- Emory University Hospital - Atlanta
- Winship Cancer Institute - Atlanta
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Iowa
- State University of Iowa, Division of Sponsored Programs - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2028-02-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05675449
The ClinicalTrials.gov registry entry for NCT05675449 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Elranatamab is the first listed.
NCT05675449 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT05675449 about?
NCT05675449 is a clinical study titled "A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma". The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination wi...
What is the current status of trial NCT05675449?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2022-12-14. Estimated completion is 2028-02-29.
What conditions does trial NCT05675449 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05675449?
The interventions under investigation include: Elranatamab (DRUG), Carfilzomib (DRUG), Maplirpacept (DRUG).
Who is sponsoring clinical trial NCT05675449?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05675449 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.